bioMerieux (OTCMKTS:BMXMF) Shares Gap Up – Still a Buy?

bioMerieux (OTCMKTS:BMXMF)’s share price gapped up prior to trading on Wednesday. The stock had previously closed at $83.27, but opened at $88.6650. bioMerieux shares last traded at $88.6650, with a volume of 51 shares.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Zacks Research raised bioMerieux from a “strong sell” rating to a “hold” rating in a research report on Monday. Morgan Stanley reiterated an “underweight” rating on shares of bioMerieux in a research report on Friday, September 11th. Piper Sandler initiated coverage on bioMerieux in a research note on Thursday, June 11th. They issued a “neutral” rating for the company. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of bioMerieux in a research note on Wednesday, June 17th. Five research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce”.

bioMerieux Stock Up 6.5%

The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.48 and a current ratio of 2.39. The company’s 50-day moving average price is $82.98 and its two-hundred day moving average price is $87.89.

About bioMerieux

bioMérieux is a France-based healthcare company specializing in in vitro diagnostics. The company develops, manufactures and markets diagnostic systems, reagents and software used to detect infectious diseases, support antimicrobial therapy decisions and assist with disease management.

Its product portfolio includes solutions for microbiology, molecular biology, immunoassays and syndromic testing. bioMérieux’s systems are used by hospitals, clinical laboratories and healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetics industries by helping customers monitor contamination, quality and safety.

Founded in 1963 by Alain Mérieux, bioMérieux traces its heritage to the Mérieux family’s work in medical diagnostics.